Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Wu Capital
BioCentury | May 13, 2022
Emerging Company Profile
Nuvig: bringing immune homeostasis to inflammatory disease with a $47M A round
Backed by Novo Holdings and Platanus, Nuvig is designing proteins to selectively suppress active immune pathways
BioCentury | Jan 6, 2022
Finance
Jan. 5 Quick Takes: Eventide leads mega-round by Korro
Plus Saliogen raises $115M series B and updates from
BioCentury | Aug 18, 2021
Emerging Company Profile
Ranok: a chaperone-based approach to targeted degradation
Emerging Company Profile: Ranok has raised $40M to test whether alternative to PROTACs could have safety, dosing advantages
BioCentury | Nov 14, 2020
Emerging Company Profile
Ex-Mavupharma execs reunite at Inipharm to build liver disease pipeline
Emerging Company Profile: Inipharm will use its $35M series A to advance lead liver program through Phase I
BioCentury | Oct 20, 2020
Deals
Oct. 19 Quick Takes: Genesis, Genentech in AI drug discovery deal; plus Endo-BioSpecifics, Gemini, Catalyst-Jacobus, ONK, Venclexta
Genesis and Genentech collaborate to identify drug candidates using AIStanford spinout and AI platform company Genesis Therapeutics Inc. entered into a collaboration agreement with the
BioCentury | Sep 10, 2020
Finance
Korro Bio’s $91.5M series A brings in new investors, launches hunt for CEO
Korro Bio’s $91.5 million series A round opens the door to new leadership for the Atlas-built RNA editing company, which has been led by Executive Chairman Nessan Bermingham since its
BioCentury | Jul 22, 2020
Finance
July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain
BioCentury | Mar 4, 2020
Finance
March 3 Quick Takes: Megarounds for Akouos, Element; plus venture rounds by Kahr, Primmune, Lipidio and Scipio and more
BioCentury | Jan 11, 2020
Financial News
Pact’s $75M series C gives Vida’s Kite alumni long-sought stab at personalized cell therapy
BioCentury | Oct 11, 2019
Product Development
What’s next for neoantigens
The next act for neoantigens includes cell therapies and a broader range of targets
Items per page:
1 - 10 of 13